Trial Profile
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Inotuzumab ozogamicin (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2023 Interventional Study Model has been changed to Parallel from Single Group Assignment, number of treatment arms changed to 4, primary endpoints has been amended.
- 25 Jun 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 25 Jun 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.